Patricia Bougie-Gomez
Nantes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target.
Journal: Leukemia
Published: September 20, 2024
CRCI2NA inaugural symposium: A meeting on tumor and immune ecosystems.
Journal: Biology of the cell
Published: August 28, 2024
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.
Journal: HemaSphere
Published: April 16, 2024
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.
Journal: Frontiers in oncology
Published: March 29, 2023
Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
Journal: Cells
Published: February 04, 2020
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Journal: Cell death & disease
Published: January 28, 2020
Disruption of IRE1α through its kinase domain attenuates multiple myeloma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 03, 2019
BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker.
Journal: Frontiers in oncology
Published: October 09, 2018
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Journal: Journal of hematology & oncology
Published: July 12, 2018
Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers.
Journal: Oncogene
Published: June 20, 2018
Last Updated: 09/26/2026